Publication: A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis
1
Issued Date
2000-12-01
Resource Type
ISSN
0125877X
Other identifier(s)
2-s2.0-0034525394
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.18, No.3 (2000), 127-133
Suggested Citation
C. Bunnag, P. Jareoncharsri, P. Tunsuriyawong, P. Pumhirun, S. Limprasertsiri, L. Chochaipanichnon, P. Supiyaphun, S. Kongpatanakul A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis. Asian Pacific Journal of Allergy and Immunology. Vol.18, No.3 (2000), 127-133. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/25957
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis
Other Contributor(s)
Abstract
An open-label, non-comparative study was performed in three Otolaryngology centers in Bangkok, Thailand, to assess the efficacy, safety and tolerability of fexofenadine in Thai patients with perennial allergic rhinitis. Altogether 101 perennial allergic rhinitis patients were included, 33 males and 68 females. Mean age was 33 years, average duration of symptoms was 6 years. All patients received fexofenadine hydrochloride 120 mg once daily (OD) in the morning for 2 weeks. Patients recorded their allergy symptoms daily using a 5 point rating scales in the diary card. At the end of 2 weeks, patients and investigators assessed the overall efficacy of treatment. Adverse events and onset of symptom relief were also recorded by every patient. Blood test and ECG were performed before and after treatment in one center (Siriraj Hospital). Total symptom scores and nasal scores decreased significantly from a baseline at 1 week and 2 weeks after treatment (p < 0.05). The mean onset of symptom relief was 2 hours and 12 minutes. The global assessment of the treatment by patients and investigators showed significant concordance. There was no significant change in either the vital signs, laboratory tests or ECG. The incidence of treatment related adverse events was 8% but all were mild and easily tolerated. Drowsiness was reported from only one patient. This study suggests that fexofenadine 120 mg once daily was an effective, safe and well tolerated treatment for perennial allergic rhinitis in Thai patients.